

Bassel F El-Rayes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3670026/publications.pdf>

Version: 2024-02-01

370
papers

11,760
citations

23544
58
h-index

39638
94
g-index

379
all docs

379
docs citations

379
times ranked

16675
citing authors

#	ARTICLE	IF	CITATIONS
1	Correlates of financial toxicity in adult cancer patients and their informal caregivers. Supportive Care in Cancer, 2022, 30, 217-225.	1.0	34
2	Epigenetics in hepatocellular carcinoma. Seminars in Cancer Biology, 2022, 86, 622-632.	4.3	64
3	Neoadjuvant treatment of pancreatic carcinosarcoma: a case report and review of literature. Chinese Clinical Oncology, 2022, 11, 8-8.	0.4	3
4	Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors. Oncology, 2022, 100, 131-139.	0.9	5
5	Phase Ib/II trial of siltuximab and spartalizumab in patients in metastatic pancreatic cancer.. Journal of Clinical Oncology, 2022, 40, TPS626-TPS626.	0.8	1
6	A phase I study of pharmacokinetic (PK)-driven sequential dosing of rucaparib (RUB) with irinotecan liposome (nal-IRI) and fluorouracil (5FU) in metastatic gastrointestinal (mGI) and pancreas (PANC) cancers.. Journal of Clinical Oncology, 2022, 40, 563-563.	0.8	0
7	Characteristics and outcomes of patients with multiple synchronous colon cancer primaries.. Journal of Clinical Oncology, 2022, 40, 194-194.	0.8	0
8	Impact of local therapy on survival among patients with metastatic anal squamous cell carcinoma.. Journal of Clinical Oncology, 2022, 40, 4-4.	0.8	0
9	Epidemiology of early esophageal adenocarcinoma. Clinical Endoscopy, 2022, 55, 372-380.	0.6	10
10	Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology. Frontiers in Oncology, 2022, 12, 821903.	1.3	2
11	Frontline therapy for advanced hepatocellular carcinoma: an update. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210861.	1.4	13
12	Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer. Oncologist, 2022, 27, 740-750.	1.9	2
13	Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report. Oncology Research and Treatment, 2022, 45, 430-437.	0.8	5
14	Impact of metformin on clinical outcomes in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors.. Journal of Clinical Oncology, 2022, 40, 4118-4118.	0.8	0
15	Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer. Clinical Cancer Research, 2022, 28, 4336-4345.	3.2	3
16	Should Signet Ring Cell Histology Alter the Treatment Approach for Clinical Stage I Gastric Cancer?. Annals of Surgical Oncology, 2021, 28, 97-105.	0.7	6
17	Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer. Molecular Cancer Therapeutics, 2021, 20, 150-160.	1.9	30
18	Is adjuvant chemotherapy beneficial for stage II-III goblet cell carcinoid/goblet cell adenocarcinoma of the appendix?. Surgical Oncology, 2021, 36, 120-129.	0.8	7

#	ARTICLE	IF	CITATIONS
19	Perioperative therapy in metastatic colorectal cancer: Pattern of use and survival outcomes. Journal of Surgical Oncology, 2021, 123, 596-605.	0.8	3
20	Phase II trial of nivolumab and metformin in patients with treatment refractory microsatellite stable metastatic colorectal cancer.. Journal of Clinical Oncology, 2021, 39, 95-95.	0.8	5
21	Survival analysis of colorectal cancer patients treated with first-line modified FOLFOX6 with or without bolus fluorouracil.. Journal of Clinical Oncology, 2021, 39, 35-35.	0.8	2
22	Survival outcomes of adjuvant chemotherapy in elderly patients with stage III colon cancer.. Journal of Clinical Oncology, 2021, 39, 89-89.	0.8	0
23	Impact of primary tumor size/horizontal extent on survival in colorectal cancer.. Journal of Clinical Oncology, 2021, 39, 125-125.	0.8	0
24	Impact of high-risk features for stage II adenocarcinoma of the appendix. Cancer Treatment and Research Communications, 2021, 27, 100329.	0.7	1
25	Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040.. Journal of Clinical Oncology, 2021, 39, 269-269.	0.8	37
26	Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status. Frontiers in Oncology, 2021, 11, 592351.	1.3	9
27	Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer. Oncologist, 2021, 26, 668-675.	1.9	20
28	Survival Outcomes of Acinar Cell Pancreatic Cancer. Pancreas, 2021, 50, 529-536.	0.5	1
29	Clinical features and outcomes of colloid carcinoma of pancreas compared to pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, 2021, 39, e16259-e16259.	0.8	0
30	Treatment outcomes for stage T1b-2 esophagogastric adenocarcinomas.. Journal of Clinical Oncology, 2021, 39, e16085-e16085.	0.8	0
31	Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective Review. Clinical Colorectal Cancer, 2021, 20, 153-160.	1.0	3
32	A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186. Cancer Immunology, Immunotherapy, 2021, 70, 3337-3348.	2.0	16
33	PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus. Molecular Cancer Therapeutics, 2021, 20, 1836-1845.	1.9	14
34	Targeting KRAS in pancreatic cancer: new drugs on the horizon. Cancer and Metastasis Reviews, 2021, 40, 819-835.	2.7	41
35	CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. Journal of Hepatology, 2021, 75, 600-609.	1.8	127
36	Phase II randomized, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198).. Journal of Clinical Oncology, 2021, 39, 413-413.	0.8	3

#	ARTICLE	IF	CITATIONS
37	Impact of socioeconomic status (SES) on colorectal cancer patient survival: An analysis of 890,867 patients in the National Cancer Database (NCDB).. Journal of Clinical Oncology, 2021, 39, 19-19.	0.8	1
38	Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 74-81.	0.6	36
39	High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer. Frontiers in Oncology, 2021, 11, 755113.	1.3	7
40	Role of Resection of the Primary in Metastatic Well-Differentiated Neuroendocrine Tumors. Pancreas, 2021, 50, 1382-1391.	0.5	2
41	Predictive and Prognostic Effects of Primary Tumor Size on Colorectal Cancer Survival. Frontiers in Oncology, 2021, 11, 728076.	1.3	10
42	STAT3 Inhibition for Gastroenteropancreatic Neuroendocrine Tumors: Potential for a New Therapeutic Target?. Journal of Gastrointestinal Surgery, 2020, 24, 1138-1148.	0.9	5
43	Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. Cancer, 2020, 126, 575-582.	2.0	65
44	In-hospital 30-day mortality for older patients with pancreatic cancer undergoing pancreaticoduodenectomy. Journal of Geriatric Oncology, 2020, 11, 660-667.	0.5	13
45	Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy. Cancer, 2020, 126, 37-45.	2.0	11
46	Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. Oncologist, 2020, 25, e528-e535.	1.9	44
47	Clinicopathological features and survival outcomes of rare histologic variants of gallbladder cancer. Journal of Surgical Oncology, 2020, 121, 294-302.	0.8	8
48	Correlation Patterns Among B7 Family Ligands and Tryptophan Degrading Enzymes in Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 1632.	1.3	5
49	Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib. JAMA Oncology, 2020, 6, e204564.	3.4	746
50	Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer. Cancer, 2020, 126, 4136-4147.	2.0	6
51	Variant anatomy of the biliary system as a cause of pancreatic and peri-ampullary cancers. Hpb, 2020, 22, 1675-1685.	0.1	10
52	Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease. British Journal of Cancer, 2020, 123, 1377-1386.	2.9	4
53	Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. British Journal of Cancer, 2020, 123, 1228-1234.	2.9	6
54	HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target. Surgical Oncology, 2020, 35, 460-465.	0.8	1

#	ARTICLE	IF	CITATIONS
55	Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer. , 2020, 8, e001100.		18
56	Frequency and clinicopathologic associations of DNA mismatch repair protein deficiency in ampullary carcinoma: Routine testing is indicated. Cancer, 2020, 126, 4788-4799.	2.0	14
57	Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer. Cancer, 2020, 126, 3360-3371.	2.0	18
58	Morphologic Variants of Pancreatic Neuroendocrine Tumors: Clinicopathologic Analysis and Prognostic Stratification. Endocrine Pathology, 2020, 31, 239-253.	5.2	28
59	Young Adults With Pancreatic Cancer. Pancreas, 2020, 49, 341-354.	0.5	12
60	A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 2497-2505.	3.2	9
61	Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer. Pancreas, 2020, 49, 822-829.	0.5	2
62	Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers. Oncologist, 2020, 25, 414-421.	1.9	11
63	Nonbacterial Thrombotic Endocarditis and Widespread Skin Necrosis in Newly Diagnosed Lung Adenocarcinoma. Case Reports in Oncology, 2020, 13, 239-244.	0.3	4
64	Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer Living With HIV: A Perspective on Recent Progress and Future Needs. JCO Oncology Practice, 2020, 16, 319-325.	1.4	15
65	Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy. JCI Insight, 2020, 5, .	2.3	31
66	Blood-based next-generation sequencing analysis of neuroendocrine neoplasms. Oncotarget, 2020, 11, 1749-1757.	0.8	29
67	Abstract 5571: Turning up the heat on pancreatic ductal adenocarcinoma via inhibiting vasoactive intestinal peptide signaling. , 2020, , .		0
68	Is adjuvant chemotherapy beneficial for stage II-III goblet cell tumors of the appendix?. Journal of Clinical Oncology, 2020, 38, 796-796.	0.8	0
69	Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations. World Journal of Gastroenterology, 2020, 26, 4036-4054.	1.4	27
70	Immunotherapy in Pancreatic Cancer. Digestive Disease Interventions, 2020, 04, 351-357.	0.3	1
71	330â€¦Investigating the clinical safety, efficacy, and immune modulation of combined XL888 and pembrolizumab in metastatic gastrointestinal malignancies. , 2020, , .		0
72	819â€¦Targeting vasoactive intestinal peptide receptor signaling: a novel approach to enhance anti-tumor response in pancreatic ductal adenocarcinoma. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
73	Racial Disparities, Outcomes, and Surgical Utilization among Hispanics with Esophageal Cancer: A Surveillance, Epidemiology, and End Results Program Database Analysis. <i>Oncology</i> , 2019, 97, 49-58.	0.9	12
74	<p>Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma</p>. <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 119-129.	1.8	15
75	A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2499-2511.	1.1	14
76	Analysis of racial disparities in the treatment and outcomes of colorectal cancer in young adults. <i>Cancer Epidemiology</i> , 2019, 63, 101618.	0.8	26
77	Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic metastasis of pancreaticobiliary origin. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 944-956.	0.6	11
78	Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. <i>British Journal of Cancer</i> , 2019, 121, 809-818.	2.9	232
79	Interaction of heat shock protein 90 with hypoxia inducible factor and signal transducer and activator of transcription in colon cancer. <i>Process Biochemistry</i> , 2019, 86, 151-158.	1.8	3
80	Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. <i>BMC Cancer</i> , 2019, 19, 857.	1.1	88
81	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2019, 111, 782-794.	3.0	223
82	National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer. <i>Cancer</i> , 2019, 125, 2732-2746.	2.0	19
83	FRI-499-Efficacy and hepatic safety of nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040. <i>Journal of Hepatology</i> , 2019, 70, e619.	1.8	4
84	Nonsurgical Management of Rectal Cancer. <i>Journal of Oncology Practice</i> , 2019, 15, 123-131.	2.5	16
85	Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer. <i>International Journal of Cancer</i> , 2019, 145, 1529-1537.	2.3	46
86	Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. <i>Investigational New Drugs</i> , 2019, 37, 1198-1206.	1.2	11
87	Cyclooxygenase-2 in gastrointestinal malignancies. <i>Cancer</i> , 2019, 125, 1221-1227.	2.0	31
88	Clinical Outcomes of Small Bowel Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2019, 18, 257-268.	1.0	24
89	Induction Therapy in Localized Pancreatic Cancer. <i>Pancreas</i> , 2019, 48, 913-919.	0.5	7
90	Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 331-336.	0.6	5

#	ARTICLE	IF	CITATIONS
91	PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors. <i>Cancers</i> , 2019, 11, 1902.	1.7	22
92	High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. <i>Oncologist</i> , 2019, 24, 911-920.	1.9	39
93	Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1453-1461.	1.9	75
94	Curcumin analogs: Their roles in pancreatic cancer growth and metastasis. <i>International Journal of Cancer</i> , 2019, 145, 10-19.	2.3	33
95	Autotaxin determines colitis severity in mice and is secreted by B cells in the colon. <i>FASEB Journal</i> , 2019, 33, 3623-3635.	0.2	28
96	Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. <i>British Journal of Cancer</i> , 2019, 120, 165-171.	2.9	279
97	Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 1-8.	0.6	31
98	Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. <i>Cancer</i> , 2019, 125, 57-67.	2.0	15
99	The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced stage cancer treated with immunotherapy. <i>Cancer</i> , 2019, 125, 127-134.	2.0	120
100	Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 269-275.	0.6	6
101	Abstract 4074: Heat shock protein 90 inhibitors alter pancreatic stellate cell cytokine production and enhances the efficacy of immune checkpoint blockade in pancreatic cancer. , 2019, , .		1
102	Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4012-4012.	0.8	178
103	Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.. <i>Journal of Clinical Oncology</i> , 2019, 37, 327-327.	0.8	80
104	Impact of genomic alterations (GAs) on outcomes and their distribution by age groups in metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2019, 37, 560-560.	0.8	2
105	TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial. <i>JMIR Research Protocols</i> , 2019, 8, e11545.	0.5	27
106	Novel Strategies on the Horizon for Metastatic Pancreatic Cancer Management. <i>Oncology & Hematology Review</i> , 2019, 15, 27.	0.2	2
107	Small Bowel and Appendix Cancers. , 2019, , 97-107.		0
108	Genomic alterations in appendiceal carcinoma using circulating DNA.. <i>Journal of Clinical Oncology</i> , 2019, 37, 658-658.	0.8	20

#	ARTICLE	IF	CITATIONS
109	Abstract B176: Sequential immunotherapy and association with clinical outcomes in advanced-stage cancer patients. , 2019, , .		0
110	Phase II randomized, double-blind, study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients hcrn GI14-198.. Journal of Clinical Oncology, 2019, 37, TPS475-TPS475.	0.8	0
111	Clinical outcomes of hepatocellular carcinoma variants compared to hepatocellular carcinoma.. Journal of Clinical Oncology, 2019, 37, 435-435.	0.8	1
112	Blood-based next-generation sequencing analysis of neuroendocrine tumors.. Journal of Clinical Oncology, 2019, 37, 4110-4110.	0.8	0
113	Analysis of age, tumor-sidedness, and mismatch repair (MMR) genes with response to immune checkpoint inhibitors (ICIs) in MMR-deficient (dMMR) colorectal cancer (CRC) patients (pts): A multi-institutional study.. Journal of Clinical Oncology, 2019, 37, e15029-e15029.	0.8	0
114	Role of resection of the primary in metastatic well/intermediate-differentiated neuroendocrine tumor (NET).. Journal of Clinical Oncology, 2019, 37, e15693-e15693.	0.8	1
115	Perioperative therapy in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2019, 37, e18231-e18231.	0.8	0
116	Personalized T cell therapy for metastatic colon cancer.. Journal of Clinical Oncology, 2019, 37, e15183-e15183.	0.8	0
117	Abstract 713: BBI-608 modulates DNA repair pathways, induces apoptosis and impacts response to 5-Fluorouracil and ionizing radiation in pancreatic cancer cells. , 2019, , .		0
118	Abstract 1205: Targeting vasoactive intestinal peptide signaling to enhance pancreatic cancer responsiveness to immunotherapy. , 2019, , .		1
119	Abstract 205: BBI-608 enhances the activity of chemoradiotherapy in colorectal cancer pre-clinical models. , 2019, , .		0
120	Abstract 3398: Interaction of STAT proteins with genistein: A computational analysis. , 2019, , .		0
121	Abstract 4074: Heat shock protein 90 inhibitors alter pancreatic stellate cell cytokine production and enhances the efficacy of immune checkpoint blockade in pancreatic cancer. , 2019, , .		0
122	Abstract B59: IL-6 regulates CTLA4 expression on CD4+ T-cells and dual antibody blockade of IL-6 and CTLA4 leads to tumor regression in an orthotopic murine model of pancreatic ductal adenocarcinoma. , 2019, , .		1
123	Abstract A55: Pancreatic stellate cells promote pancreatic cancer invasion and metastasis by secretion of soluble factors and through contact-mediated mechanisms. , 2019, , .		0
124	Abstract 3621: Targeted hyaluronic acid nanoparticles improve treatment response in pancreatic cancer. , 2019, , .		0
125	Abstract 3967: Comparison of neoadjuvant FOLFIRINOX alone vs FOLFIRINOX + stereotactic body radiation as immune-modulators of the pancreatic adenocarcinoma microenvironment. , 2019, , .		0
126	Abstract 2561: DNA-PKCS deacetylation by SIRT2 promotes DNA double-strand break repair by non-homologous end joining. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
127	Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases. <i>Cancer</i> , 2018, 124, 1992-2000.	2.0	17
128	Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 659-670.	1.1	18
129	A patient-centered team approach in oncology. <i>Cancer</i> , 2018, 124, 1856-1858.	2.0	2
130	Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis. <i>Oncologist</i> , 2018, 23, 704-711.	1.9	15
131	Chemotherapy with or Without Definitive Radiation Therapy in Inoperable Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 1026-1033.	0.7	9
132	Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 201-207.	2.0	16
133	Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease. <i>Annals of Surgical Oncology</i> , 2018, 25, 290-298.	0.7	15
134	Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis. <i>Journal of Gastrointestinal Oncology</i> , 2018, 10, 85-94.	0.6	24
135	Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles. <i>Molecular Cancer</i> , 2018, 17, 177.	7.9	80
136	The Potential of CAR T Cell Therapy in Pancreatic Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 2166.	2.2	92
137	Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. <i>Cancer</i> , 2018, 124, 3118-3126.	2.0	23
138	Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials. <i>Oncology</i> , 2018, 95, 138-146.	0.9	7
139	Abstract 5816: Inhibition of Hsp90 sensitizes pancreatic cancer in vitro and in vivo to chemo-radiotherapy. <i>Cancer Research</i> , 2018, 78, 5816-5816.	0.4	1
140	Phase 1b/2 trial of cancer stemness inhibitor napabucasin (NAPA) + nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4110-4110.	0.8	11
141	Adjuvant treatment for resected sub-centimeter T1 pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4125-4125.	0.8	1
142	Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16207-e16207.	0.8	2
143	Epidemiology and treatment of high-grade gastrointestinal neuroendocrine tumors (HG-GI-NETs).. <i>Journal of Clinical Oncology</i> , 2018, 36, 421-421.	0.8	1
144	Phase Ib trial of pembrolizumab and XL888 in patients with advanced gastrointestinal malignancies.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS526-TPS526.	0.8	3

#	ARTICLE	IF	CITATIONS
145	Molecularly Targeted Therapies in Pancreatic Cancer. , 2018, , 219-233.		0
146	Resection of pancreatic cancer following induction chemotherapy.. Journal of Clinical Oncology, 2018, 36, 406-406.	0.8	0
147	STAT3 inhibition for gastroenteropancreatic neuroendocrine tumors: Potential for a new therapeutic target?. Journal of Clinical Oncology, 2018, 36, 340-340.	0.8	0
148	Incidence, treatment and survival outcomes of small bowel adenocarcinomas: A National Cancer Database (NCDB) analysis.. Journal of Clinical Oncology, 2018, 36, e16262-e16262.	0.8	2
149	Impact of adjuvant chemotherapy in higher risk stage II colon cancer with a deficient mismatch repair (dMMR)/ microsatellite instability-high (MSI-H) profile.. Journal of Clinical Oncology, 2018, 36, 3604-3604.	0.8	0
150	Survival outcomes in gastric and gastroesophageal junction adenocarcinoma treated with peri-operative chemotherapy with or without pre-operative radiotherapy.. Journal of Clinical Oncology, 2018, 36, 4026-4026.	0.8	0
151	A phase I/II study of trifluridine/tipiracil (TAS-102) in combination with nanoliposomal irinotecan (NAL-IRI) in advanced GI cancers.. Journal of Clinical Oncology, 2018, 36, TPS4155-TPS4155.	0.8	1
152	Retrospective study of the safety of administering pegfilgrastim on the same day of 5- Fluorouracil pump disconnect.. Journal of Clinical Oncology, 2018, 36, e16190-e16190.	0.8	0
153	Early change in blood-based biomarkers and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO).. Journal of Clinical Oncology, 2018, 36, e15022-e15022.	0.8	0
154	Abstract LB-232: Derazantinib (ARQ 087) pharmacodynamics: Alterations in FGF19/21/23 and phosphate in patients with cholangiocarcinoma. , 2018, , .		0
155	Abstract 2607: Blood based biomarkers and association with clinical outcome (CO) in advanced stage patients (pts) treated with immunotherapy (IO). , 2018, , .		0
156	Incidence and Survival of Appendiceal Mucinous Neoplasms. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 569-573.	0.6	45
157	Novel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancer. Molecular Carcinogenesis, 2017, 56, 288-299.	1.3	35
158	Identifying and targeting cancer stem cells in the treatment of gastric cancer. Cancer, 2017, 123, 1303-1312.	2.0	89
159	Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group/American College of Radiology Imaging Network Cancer Research Group Trial (E3205). Journal of Clinical Oncology, 2017, 35, 718-726.	0.8	70
160	Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base. Cancer, 2017, 123, 3476-3485.	2.0	35
161	Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer. Cancer Letters, 2017, 402, 110-116.	3.2	19
162	Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells. Cancer, 2017, 123, 4924-4933.	2.0	20

#	ARTICLE	IF	CITATIONS
163	Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor. <i>Oncology</i> , 2017, 93, 336-342.	0.9	13
164	Appendiceal Mucinous Neoplasms: Diagnosis and Management. <i>Oncologist</i> , 2017, 22, 1107-1116.	1.9	131
165	Non-ampullary duodenal carcinomas: clinicopathologic analysis of 47 cases and comparison with ampullary and pancreatic adenocarcinomas. <i>Modern Pathology</i> , 2017, 30, 255-266.	2.9	36
166	Emergency use of uridine triacetate for the prevention and treatment of life-threatening fluorouracil and capecitabine toxicity. <i>Cancer</i> , 2017, 123, 345-356.	2.0	91
167	A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2017, 117, 1592-1599.	2.9	77
168	Establishment of human metastatic colorectal cancer model in rabbit liver: A pilot study. <i>PLoS ONE</i> , 2017, 12, e0177212.	1.1	3
169	A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3541-3541.	0.8	53
170	ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4017-4017.	0.8	24
171	BBI608-503-103HCC: A phase Ib/II clinical study of napabucasin (BBI608) in combination with sorafenib or amcasertib (BBI503) in combination with sorafenib (Sor) in adult patients with hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4077-4077.	0.8	9
172	A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4106-4106.	0.8	13
173	HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for novel therapeutic targets.. <i>Journal of Clinical Oncology</i> , 2017, 35, 235-235.	0.8	2
174	Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2017, 35, 593-593.	0.8	11
175	Long -Term Survival in Stage IV Esophageal Adenocarcinoma with Chemoradiation and Serial Endoscopic Cryoablation. <i>Clinical Endoscopy</i> , 2017, 50, 491-494.	0.6	5
176	Safety and pharmacokinetics of crizotinib in patients (pts) with hepatic impairment (HI) and advanced cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2552-2552.	0.8	0
177	Treatment, outcomes, and impact of racial disparities on young adults with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18069-e18069.	0.8	0
178	Enrollment into molecular selection trials and impact on patient disposition.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14035-e14035.	0.8	0
179	Safety of trifluridine/tipiracil for metastatic colorectal cancer in African American patients participating in an expanded access program.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15039-e15039.	0.8	0
180	Chemotherapy with or without definitive radiation therapy in locally advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4103-4103.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Phase IB study of induction chemotherapy with XELOX, followed by radiation therapy, carboplatin, and everolimus in patients with locally advanced esophageal cancer (EC).. Journal of Clinical Oncology, 2017, 35, e15607-e15607.	0.8	0
182	Racial disparities in treatment and outcomes of colorectal cancer in young adults.. Journal of Clinical Oncology, 2017, 35, 6559-6559.	0.8	1
183	Long-term Survival in Stage IV Esophageal Adenocarcinoma with Chemoradiation and Serial Endoscopic Cryoablation. American Journal of Gastroenterology, 2016, 111, S753-S754.	0.2	0
184	Combination of Tolfenamic acid and curcumin induces colon cancer cell growth inhibition through modulating specific transcription factors and reactive oxygen species. Oncotarget, 2016, 7, 3186-3200.	0.8	50
185	Taking aim at the genomic diversity of gastrointestinal cancers: a changing landscape. Journal of Gastrointestinal Oncology, 2016, 7, 673-674.	0.6	0
186	Treatment allocation in patients with early-stage esophageal adenocarcinoma: Prevalence and predictors of lymph node involvement. Cancer, 2016, 122, 2150-2157.	2.0	35
187	Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors. Targeted Oncology, 2016, 11, 807-814.	1.7	4
188	Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Molecular Therapy, 2016, 24, 1150-1158.	3.7	114
189	A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458). International Journal of Radiation Oncology Biology Physics, 2016, 96, 296-303.	0.4	61
190	Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. Medical Oncology, 2016, 33, 48.	1.2	20
191	Prolonged survival in pancreatic cancer patients with increased regucalcin gene expression: Overexpression of regucalcin suppresses the proliferation in human pancreatic cancer MIA PaCa-2 cells in vitro. International Journal of Oncology, 2016, 48, 1955-1964.	1.4	35
192	FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncology, The, 2016, 17, 801-810.	5.1	719
193	Prolonged survival in hepatocarcinoma patients with increased regucalcin gene expression: HepG2 cell proliferation is suppressed by overexpression of regucalcin in vitro. International Journal of Oncology, 2016, 49, 1686-1694.	1.4	26
194	Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial. Journal of Surgical Oncology, 2016, 114, 336-341.	0.8	8
195	Ampullary carcinoma is often of mixed or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreatobiliary versus intestinal in 232 cases. Modern Pathology, 2016, 29, 1575-1585.	2.9	56
196	An update on the multimodality of localized rectal cancer. Critical Reviews in Oncology/Hematology, 2016, 108, 23-32.	2.0	5
197	Adenocarcinoma ex-goblet cell carcinoid (appendiceal-type crypt cell adenocarcinoma) is a morphologically distinct entity with highly aggressive behavior and frequent association with peritoneal/intra-abdominal dissemination: an analysis of 77 cases. Modern Pathology, 2016, 29, 1243-1253.	2.9	53
198	Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies. Journal of Molecular Diagnostics, 2016, 18, 299-315.	1.2	55

#	ARTICLE	IF	CITATIONS
199	Aquaporins: Their role in gastrointestinal malignancies. <i>Cancer Letters</i> , 2016, 373, 12-18.	3.2	45
200	Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib. <i>European Journal of Cancer</i> , 2016, 52, 109-119.	1.3	38
201	Small molecule tolfenamic acid and dietary spice curcumin treatment enhances antiproliferative effect in pancreatic cancer cells via suppressing Sp1, disrupting NF- κ B translocation to nucleus and cell cycle phase distribution. <i>Journal of Nutritional Biochemistry</i> , 2016, 31, 77-87.	1.9	42
202	Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System (pT1: \leq 2, pT2: \leq 4, pT3: \leq 4 cm) is More Valid and Clinically Relevant. <i>Annals of Surgical Oncology</i> , 2016, 23, 2010-2018.	0.7	107
203	Adjuvant therapy for pancreas cancer in an era of value based cancer care. <i>Cancer Treatment Reviews</i> , 2016, 42, 10-17.	3.4	16
204	Inhibition of NF- κ B translocation by curcumin analogs induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer. <i>Cancer Letters</i> , 2016, 373, 227-233.	3.2	63
205	Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer. <i>Oncologist</i> , 2016, 21, 178-187.	1.9	47
206	MicroRNAs as biomarkers and prospective therapeutic targets in colon and pancreatic cancers. <i>Tumor Biology</i> , 2016, 37, 97-104.	0.8	11
207	Phase 1b extension study of cancer stemness inhibitor BB608 (napabucasin) administered in combination with FOLFIRI +/- bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3564-3564.	0.8	3
208	Uridine triacetate as a life-saving antidote to capecitabine toxicity.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21612-e21612.	0.8	1
209	Clinical trial experience with uridine triacetate for 5-fluorouracil toxicity.. <i>Journal of Clinical Oncology</i> , 2016, 34, 655-655.	0.8	1
210	Appendiceal Neuroendocrine, Goblet and Signet-Ring Cell Tumors: A Spectrum of Diseases with Different Patterns of Presentation and Outcome. <i>Cancer Research and Treatment</i> , 2016, 48, 596-604.	1.3	30
211	A phase 1b study of cancer stem cell (CSC) pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 284-284.	0.8	3
212	A molecular biomarker targeted approach to adjuvant therapy for resected pancreatic adenocarcinoma: Results of a phase II prospective trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 230-230.	0.8	1
213	Phase 1b trial of gemcitabine with yttrium-90 in patients with hepatic tumors of pancreatobiliary origin.. <i>Journal of Clinical Oncology</i> , 2016, 34, 460-460.	0.8	19
214	Uridine triacetate as a lifesaving antidote for overdoses and severe early-onset 5-fluorouracil and capecitabine toxicities.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21689-e21689.	0.8	0
215	Comparative features and overall survival in adenosquamous carcinoma, a rare tumor of the esophagus.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15541-e15541.	0.8	0
216	Uridine triacetate for early onset, severe life-threatening toxicities of 5-fluorouracil and capecitabine.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21675-e21675.	0.8	0

#	ARTICLE	IF	CITATIONS
217	Effect of definitive concurrent therapy with or without surgery on resectable esophageal cancer survival: An analysis of the National Cancer Data Base.. Journal of Clinical Oncology, 2016, 34, 4045-4045.	0.8	0
218	Abstract 4818: Tolfenamic acid and curcumin treatment induces pancreatic cancer cell growth inhibition via suppressing Sp1 expression, NF- κ B translocation to nucleus. , 2016, , .		0
219	Abstract 4416: Combination of HSP90 and proteasome inhibitor is effective in pancreatic cancer. , 2016, , .		0
220	Open pipelines for integrated tumor genome profiles reveal differences between pancreatic cancer tumors and cell lines. Cancer Medicine, 2015, 4, 392-403.	1.3	8
221	Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. Journal of Surgical Oncology, 2015, 111, 1028-1034.	0.8	65
222	Clinicopathologic Features and Outcome of Young Adults With Stage IV Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 543-549.	0.6	20
223	Openâ€label prospective study of the safety and efficacy of glassâ€based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis. Cancer, 2015, 121, 2164-2174.	2.0	51
224	Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United States. World Journal of Oncology, 2015, 6, 349-354.	0.6	0
225	Biomarkers for personalized medicine in GI cancers. Molecular Aspects of Medicine, 2015, 45, 14-27.	2.7	10
226	Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al. Journal of Clinical Oncology, 2015, 33, 3842-3843.	0.8	0
227	Substaging of Lymph Node Status in Resected Pancreatic Ductal Adenocarcinoma Has Strong Prognostic Correlations: Proposal for a Revised N Classification for TNM Staging. Annals of Surgical Oncology, 2015, 22, 1187-1195.	0.7	79
228	The flavonoid p-hydroxycinnamic acid exhibits anticancer effects in human pancreatic cancer MIA PaCa-2 cells in vitro: Comparison with gemcitabine. Oncology Reports, 2015, 34, 3304-3310.	1.2	15
229	High Nuclear Hypoxia-Inducible Factor 1 Alphaâ€Expression Is a Predictor of Distant Recurrence in Patients With Resected Pancreaticâ€Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2015, 91, 631-639.	0.4	35
230	Broad targeting of angiogenesis for cancer prevention and therapy. Seminars in Cancer Biology, 2015, 35, S224-S243.	4.3	375
231	Preservation of quality of life with doxorubicin drugâ€eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1167-1174.	1.4	18
232	Visualizing cancer and response to therapy<i>in vivo</i> using Cy5.5-labeled factor VIIa and anti-tissue factor antibody. Journal of Drug Targeting, 2015, 23, 257-265.	2.1	7
233	First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United Statesâ€Based Cost-Effectiveness Analysis. Journal of Clinical Oncology, 2015, 33, 1112-1118.	0.8	144
234	Hyperthermic Intraperitoneal Chemotherapy Following Cytoreductive Surgery Improves Outcome in Patients With Primary Appendiceal Mucinous Adenocarcinoma: A Pooled Analysis From Three Tertiary Care Centers. Oncologist, 2015, 20, 907-914.	1.9	25

#	ARTICLE	IF	CITATIONS
235	Hypoxia inducible factor-1 α : Its role in colorectal carcinogenesis and metastasis. Cancer Letters, 2015, 366, 11-18.	3.2	96
236	Management patterns and predictors of mortality among US patients with cancer hospitalized for malignant bowel obstruction. Cancer, 2015, 121, 1772-1778.	2.0	26
237	Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach. Annals of Surgical Oncology, 2015, 22, 2295-2301.	0.7	93
238	Substaging Nodal Status in Ampullary Carcinomas has Significant Prognostic Value: Proposed Revised Staging Based on an Analysis of 313 Well-Characterized Cases. Annals of Surgical Oncology, 2015, 22, 4392-4401.	0.7	31
239	Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. Therapeutic Advances in Medical Oncology, 2015, 7, 56-62.	1.4	18
240	Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?. Oncologist, 2015, 20, 981-982.	1.9	26
241	Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2015, 33, 3727-3732.	0.8	86
242	Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology, 2015, 35, S276-S304.	4.3	220
243	Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer. Cancer Letters, 2015, 357, 557-565.	3.2	71
244	Heat shock protein 90 promotes epithelial to mesenchymal transition, invasion, and migration in colorectal cancer. Molecular Carcinogenesis, 2015, 54, 1147-1158.	1.3	78
245	Phase I study of ganetespib (G), capecitabine (C), and radiation (RT) in rectal cancer.. Journal of Clinical Oncology, 2015, 33, 3596-3596.	0.8	5
246	Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 6613-6613.	0.8	1
247	Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer (mPC).. Journal of Clinical Oncology, 2015, 33, 368-368.	0.8	1
248	Comprehensive genomic profiling of cancer of the appendix to reveal new routes to targeted therapies.. Journal of Clinical Oncology, 2015, 33, 608-608.	0.8	3
249	Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 658-658.	0.8	1
250	The anatomic location of pancreatic cancer as a prognostic factor for inpatient complications.. Journal of Clinical Oncology, 2015, 33, 247-247.	0.8	0
251	Prognostic value of gender in hospitalized pancreatic patients.. Journal of Clinical Oncology, 2015, 33, 256-256.	0.8	0
252	Phase Ib study of pasireotide (P), everolimus (E), and selective internal radioembolization therapy (SIRT) for unresectable neuroendocrine hepatic metastases.. Journal of Clinical Oncology, 2015, 33, 4092-4092.	0.8	0

#	ARTICLE	IF	CITATIONS
253	A risk score to predict in-hospital mortality in patients with pancreatic cancer.. Journal of Clinical Oncology, 2015, 33, e15256-e15256.	0.8	1
254	Management and outcomes of hospitalized patients with primary neuroendocrine tumor (NET) and non-NET appendiceal cancers in the United States.. Journal of Clinical Oncology, 2015, 33, e17722-e17722.	0.8	0
255	Pattern of liver-directed therapies and outcomes in cancer patients hospitalized in the United States.. Journal of Clinical Oncology, 2015, 33, e15112-e15112.	0.8	0
256	Borderline resectable (BRPC) and locally advanced unresectable (LAPC) pancreas cancer treatment: A single Institution experience.. Journal of Clinical Oncology, 2015, 33, e15260-e15260.	0.8	0
257	Abstract 2544: Combination of anti-cancer small molecule tolfenamic acid and curcumin effectively inhibits colon cancer cell growth. , 2015, , .		0
258	Abstract CT303: A phase I pharmacokinetic and pharmacodynamic evaluation of the combination of everolimus and buparlisib for concurrent mTOR and PI3K pathway blockade in patients with advanced solid tumors. , 2015, , .		0
259	Abstract 3778: Inhibition of NF- κ B translocation induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer. , 2015, , .		0
260	Abstract 699: PIK3CA/BRAF mutations negatively affect outcome of patients with KRAS wild-type metastatic colorectal cancer treated with front line anti-EGFR monoclonal antibodies: Meta-analysis results. , 2015, , .		0
261	Radiotherapy patterns of care in gastric adenocarcinoma: a single institution experience. Journal of Gastrointestinal Oncology, 2015, 6, 247-53.	0.6	2
262	Peptide Vaccines for Treatment of Colon Cancer: Have We Made Progress?. Current Colorectal Cancer Reports, 2014, 10, 477-486.	1.0	0
263	HER2 in resected gastric cancer: Is there prognostic value?. Journal of Surgical Oncology, 2014, 109, 61-66.	0.8	30
264	Survival, Efficacy, and Safety of Small Versus Large Doxorubicin Drug-Eluting Beads TACE Chemoembolization in Patients With Unresectable HCC. American Journal of Roentgenology, 2014, 203, W706-W714.	1.0	66
265	Chemotherapeutic Strategies in Advanced or Metastatic Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 194-200.	0.6	8
266	Value of Intraoperative Neck Margin Analysis During Whipple for Pancreatic Adenocarcinoma. Annals of Surgery, 2014, 260, 494-503.	2.1	88
267	Tumor Angiogenesis Therapy Using Targeted Delivery of Paclitaxel to the Vasculature of Breast Cancer Metastases. Journal of Drug Delivery, 2014, 2014, 1-12.	2.5	9
268	CHD7 Expression Predicts Survival Outcomes in Patients with Resected Pancreatic Cancer. Cancer Research, 2014, 74, 2677-2687.	0.4	34
269	Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis. Carcinogenesis, 2014, 35, 967-973.	1.3	115
270	Modified Response Evaluation Criteria in Solid Tumors and European Association for the Study of the Liver Criteria Using Delayed-Phase Imaging at an Early Time Point Predict Survival in Patients with Unresectable Intrahepatic Cholangiocarcinoma following Yttrium-90 Radioembolization. Journal of Vascular and Interventional Radiology, 2014, 25, 256-265.	0.2	86

#	ARTICLE	IF	CITATIONS
271	Targeted therapies in metastatic esophageal cancer: Advances over the past decade. Critical Reviews in Oncology/Hematology, 2014, 91, 186-196.	2.0	32
272	Cost Effectiveness Analysis of Pharmacokinetically-Guided 5-Fluorouracil in FOLFOX Chemotherapy for Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2014, 13, 219-225.	1.0	35
273	Locoregional therapies for metastatic colorectal carcinoma to the liver-An evidence-based review. Journal of Surgical Oncology, 2014, 110, 182-196.	0.8	29
274	Treatment utilization and surgical outcome of ampullary and duodenal adenocarcinoma. Journal of Surgical Oncology, 2014, 109, 556-560.	0.8	12
275	Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer. Investigational New Drugs, 2014, 32, 682-690.	1.2	9
276	Nuclear Hypoxia-Inducible Factor 1 Alpha is a Predictor of Distant Failure in Patients With Resected Pancreatic Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2014, 90, S49.	0.4	0
277	Mo1135 Trends in the Incidence of Esophageal Adenocarcinoma and Early Stage Esophageal Adenocarcinoma in the United States. Gastroenterology, 2014, 146, S-566-S-567.	0.6	4
278	Imaging and curcumin delivery in pancreatic cancer cell lines using PEGylated $\text{I}\pm\text{Gd}$ (MoO_4) $\times 3$ mesoporous particles. Dalton Transactions, 2014, 43, 3330-3338.	1.6	34
279	Cost-effectiveness analysis of pharmacokinetic-guided (PK) 5-fluorouracil (5FU) when combined with leucovorin and oxaliplatin (FOLFOX) chemotherapy for metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 6527-6527.	0.8	2
280	HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy. Oncotarget, 2014, 5, 9980-9991.	0.8	52
281	Survival trends in chemorefractory unresectable intrahepatic cholangiocarcinoma (ICC) and the effect of yttrium-90 (Y90) radioembolization: SEER versus tertiary cancer center.. Journal of Clinical Oncology, 2014, 32, 342-342.	0.8	0
282	Association of radiation therapy with overall survival in patients undergoing surgery for T3N0M0 adenocarcinoma of the rectum.. Journal of Clinical Oncology, 2014, 32, 528-528.	0.8	0
283	Open-label prospective study of safety and efficacy of glass-based Y-90 radioembolization for infiltrative HCC with PVT.. Journal of Clinical Oncology, 2014, 32, 276-276.	0.8	0
284	Survival trends in unresectable hepatocellular carcinoma and the effect of DEB-TACE: SEER versus tertiary cancer center.. Journal of Clinical Oncology, 2014, 32, 308-308.	0.8	0
285	Mortality from malignant bowel obstruction in hospitalized U.S. cancer patients.. Journal of Clinical Oncology, 2014, 32, 9626-9626.	0.8	1
286	Cost-effectiveness analysis (CEA) of bevacizumab (Bev) in first- and second-line treatment of metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 6502-6502.	0.8	0
287	Abstract 4221: HSP90 as a therapeutic target in colorectal cancer. , 2014, , .		0
288	Abstract 4216: Combination of anti-cancer small molecule tolfenamic acid and curcumin or curcumin analog EF31 effectively inhibits pancreatic cancer cell growth. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
289	Abstract 1308: Functional inhibition of HSP90 induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer. , 2014, , .		0
290	Abstract C26: Ethnic, gender, and age disparities and outcome of phase I clinical trials of biologically targeted anticancer agents. , 2014, , .		1
291	An analysis of human equilibrative nucleoside transporter ¹ , ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross ¹ complementing gene ¹ expression in patients with resected pancreas adenocarcinoma. Cancer, 2013, 119, 445-453.	2.0	42
292	Carbohydrate antigen 19 ⁹ is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine ¹ containing chemotherapy. Cancer, 2013, 119, 285-292.	2.0	103
293	Excision repair cross ¹ complementing gene ¹ , ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter ¹ expression and prognostic value in biliary tract malignancy. Cancer, 2013, 119, 454-462.	2.0	28
294	Risk Factors for Rising Incidence of Esophageal and Gastric Cardia Adenocarcinoma. Journal of Gastrointestinal Cancer, 2013, 44, 143-151.	0.6	62
295	Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1 ¹ and STAT-3. Angiogenesis, 2013, 16, 903-917.	3.7	72
296	Yttrium-90 Radioembolization for Unresectable Standard-chemorefractory Intrahepatic Cholangiocarcinoma: Survival, Efficacy, and Safety Study. CardioVascular and Interventional Radiology, 2013, 36, 440-448.	0.9	133
297	Central Venous Catheter Care for the Patient With Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2013, 31, 1357-1370.	0.8	278
298	Safety and Efficacy of Doxorubicin Drug-eluting Bead Transarterial Chemoembolization in Patients with Advanced Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2013, 24, 307-315.	0.2	68
299	Geographic differences in approach to advanced gastric cancer: Is there a standard approach?. Critical Reviews in Oncology/Hematology, 2013, 88, 416-426.	2.0	39
300	Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma. Pancreas, 2013, 42, 1311-1315.	0.5	166
301	PEGylated $\text{H}_2\text{Gd}_{2/3}(\text{MoO}_4)_3$ Mesoporous Flowers: Synthesis, Characterization, and Biological Application. Crystal Growth and Design, 2013, 13, 4051-4058.	1.4	29
302	Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer. Cancer Letters, 2013, 341, 195-203.	3.2	73
303	SPARC and DNA methylation: Possible diagnostic and therapeutic implications in gastrointestinal cancers. Cancer Letters, 2013, 328, 10-17.	3.2	28
304	In ¹ Vitro and In ¹ Vivo Enhancement of Chemoradiation Using the Oral PARP Inhibitor ABT-888 in Colorectal Cancer Cells. International Journal of Radiation Oncology Biology Physics, 2013, 86, 469-476.	0.4	55
305	mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Annals of Oncology, 2013, 24, 965-973.	0.6	109
306	90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness. Journal of Comparative Effectiveness Research, 2013, 2, 435-444.	0.6	8

#	ARTICLE	IF	CITATIONS
307	Tools to optimize the functionality of a leukemia clinical trial team. <i>Leukemia and Lymphoma</i> , 2013, 54, 110-116.	0.6	0
308	Pleiotropic effects of genistein in metabolic, inflammatory, and malignant diseases. <i>Nutrition Reviews</i> , 2013, 71, 562-572.	2.6	68
309	Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma. <i>Cancer</i> , 2013, 119, 3148-3155.	2.0	105
310	Incidence and prognosis of gastroesophageal cancer in rural, urban, and metropolitan areas of the United States. <i>Cancer</i> , 2013, 119, 4020-4027.	2.0	20
311	Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma. <i>Cancer</i> , 2013, 119, 3242-3250.	2.0	19
312	A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies. <i>British Journal of Cancer</i> , 2013, 108, 762-765.	2.9	22
313	Antiangiogenic activity of the HSP90 inhibitor ganetespib in pancreatic cancer models. <i>FASEB Journal</i> , 2013, 27, 1b572.	0.2	2
314	Markers of resistance to anti-EGFR therapy in colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 308-18.	0.6	45
315	Neuroendocrine tumors (NET) of the gastrointestinal tract: Patterns of management and experience at Winship Cancer Institute of Emory University.. <i>Journal of Clinical Oncology</i> , 2013, 31, 326-326.	0.8	0
316	Anti-angiogenic effects of curcumin and its novel analogs EF31 and UBS109 in colorectal cancer. <i>FASEB Journal</i> , 2013, 27, 1b574.	0.2	2
317	Abstract LB-168: A pilot clinical trial of chromodomain-helicase-DNA-binding protein 7 (CHD7) expression as a prognostic and predictive biomarker in patients with early-stage pancreatic adenocarcinoma.. , 2013, , .		0
318	Early therapy response assessment by apparent diffusion coefficient (ADC) quantification following glass-based yttrium-90 radioembolization for unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, e15140-e15140.	0.8	0
319	Survival outcome of ampullary and duodenal adenocarcinomas.. <i>Journal of Clinical Oncology</i> , 2013, 31, e14579-e14579.	0.8	0
320	Multiplatform assessment of anaplastic lymphoma kinase (ALK) gene rearrangement in signet ring cell carcinoma of the gastrointestinal tract.. <i>Journal of Clinical Oncology</i> , 2013, 31, e14612-e14612.	0.8	0
321	Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 707-718.	1.5	5
322	The impact of curcumin on breast cancer. <i>Integrative Biology (United Kingdom)</i> , 2012, 4, 996-1007.	0.6	74
323	Oxaliplatin-Induced Hepatoportal Sclerosis, Portal Hypertension, and Variceal Bleeding Successfully Treated With Transjugular Intrahepatic Portosystemic Shunt. <i>Clinical Colorectal Cancer</i> , 2012, 11, 224-227.	1.0	17
324	Safety and Feasibility of Same-day Discharge of Patients with Unresectable Hepatocellular Carcinoma Treated with Doxorubicin Drug-eluting Bead Transcatheter Chemoembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2012, 23, 1286-1293.e1.	0.2	26

#	ARTICLE	IF	CITATIONS
325	Abstract 3119: A synthetic lethal screen identifies genetic determinants for gemcitabine sensitivity in pancreatic cancer. <i>Cancer Research</i> , 2012, 72, 3119-3119.	0.4	5
326	Abstract 3828: Potent curcumin analogues inhibit pancreatic cancer cell growth and angiogenesis. , 2012, , .		14
327	An analysis of ERCC1, hENT1, RRM1, and RRM2 expression in resected pancreas adenocarcinoma: Implications for adjuvant treatment.. <i>Journal of Clinical Oncology</i> , 2012, 30, 206-206.	0.8	0
328	Abstract 2872: Functional inhibition of HSP90 potentiates the effects of ionizing radiation in colorectal cancer. , 2012, , .		0
329	Abstract 2326: Antiangiogenic effects associated with the inhibition of HSP90 in colorectal cancer. , 2012, , .		0
330	Novel methods of analyzing long-term trends in incidence and survival applied to gastroesophageal cancers.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14512-e14512.	0.8	0
331	Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase II trial in patients with metastatic colorectal adenocarcinoma. <i>Anticancer Research</i> , 2012, 32, 3559-63.	0.5	6
332	Differential Expression of ERCC1 in Pancreas Adenocarcinoma: High Tumor Expression is Associated with Earlier Recurrence and Shortened Survival after Resection. <i>Annals of Surgical Oncology</i> , 2011, 18, 2699-2705.	0.7	39
333	Clinically Relevant Biomarkers to Select Patients for Targeted Inhibitor Therapy after Resection of Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2011, 18, 3384-90.	0.7	21
334	A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. <i>Investigational New Drugs</i> , 2011, 29, 694-699.	1.2	52
335	Squamous Cell Cancer of the Anal Canal in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, Publish Ahead of Print, 135-9.	0.6	18
336	Impact of Race, Age, and Socioeconomic Status on Participation in Pancreatic Cancer Clinical Trials. <i>Pancreas</i> , 2010, 39, 967-971.	0.5	18
337	Clinicopathological analysis of primary epithelial appendiceal neoplasms. <i>Medical Oncology</i> , 2010, 27, 1073-1078.	1.2	8
338	Concurrent inhibition of NF- κ B, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer. <i>Journal of Cellular Biochemistry</i> , 2010, 110, 171-181.	1.2	24
339	CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010, 6, 98-105.	0.7	35
340	A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. <i>Annals of Oncology</i> , 2010, 21, 1999-2004.	0.6	89
341	Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric Cancer. <i>Case Reports in Oncology</i> , 2009, 2, 220-228.	0.3	1
342	Exploitation of protein kinase C: A useful target for cancer therapy. <i>Cancer Treatment Reviews</i> , 2009, 35, 1-8.	3.4	101

#	ARTICLE	IF	CITATIONS
343	Protein kinases C isozymes are differentially expressed in human breast carcinomas. Life Sciences, 2009, 84, 766-771.	2.0	13
344	Ritonavir mediated protection of retinoblastoma-E2F-1 complex at G1 phase of cell cycle in pancreatic cancer cell lines. Journal of the American College of Surgeons, 2008, 207, S97.	0.2	0
345	Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane <i>in vitro</i> and <i>in vivo</i> using an orthotopic model of pancreatic cancer. Molecular Cancer Therapeutics, 2008, 7, 1708-1719.	1.9	82
346	Protein Kinase C. Pancreas, 2008, 36, 346-352.	0.5	27
347	Small molecule tyrosine kinase inhibitors in pancreatic cancer. Biologics: Targets and Therapy, 2008, 2, 707.	3.0	17
348	A Phase I Study of Gemcitabine and Uracil-Ftorfar (UFT)/Leucovorin. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 101-105.	0.6	1
349	A Phase II Study of Preoperative Capecitabine and Radiation Therapy in Patients With Rectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 340-345.	0.6	24
350	Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. Cancer Chemotherapy and Pharmacology, 2007, 61, 283-289.	1.1	18
351	A phase I study of flavopiridol and docetaxel. Investigational New Drugs, 2006, 24, 305-310.	1.2	24
352	Potentiation of the Effect of Erlotinib by Genistein in Pancreatic Cancer: The Role of Akt and Nuclear Factor- κ B. Cancer Research, 2006, 66, 10553-10559.	0.4	127
353	Phase I Study of Bryostatin 1 and Gemcitabine. Clinical Cancer Research, 2006, 12, 7059-7062.	3.2	22
354	A Phase II Study of Carboplatin and Paclitaxel in Adenocarcinoma of Unknown Primary. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 152-156.	0.6	24
355	Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors. Investigational New Drugs, 2005, 23, 57-62.	1.2	10
356	A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Investigational New Drugs, 2005, 23, 583-590.	1.2	85
357	Cellular DNA content parameters as prognostic indicators in human astrocytomas. Journal of Neuro-Oncology, 2005, 71, 85-89.	1.4	6
358	Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells. Breast Cancer Research and Treatment, 2005, 90, 25-31.	1.1	17
359	Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Molecular Cancer Therapeutics, 2005, 4, 1943-1951.	1.9	65
360	Cytochrome P450 and Glutathione Transferase Expression in Squamous Cell Cancer. Clinical Cancer Research, 2004, 10, 4412-4416.	3.2	12

#	ARTICLE	IF	CITATIONS
361	Targeting the epidermal growth factor receptor. British Journal of Cancer, 2004, 91, 418-424.	2.9	151
362	A phase II study of carboplatin and paclitaxel in esophageal cancer. Annals of Oncology, 2004, 15, 960-965.	0.6	46
363	Breast Cancer in Women with Human Immunodeficiency Virus Infection: Implications for Diagnosis and Therapy. Breast Cancer Research and Treatment, 2004, 83, 189-189.	1.1	0
364	Apoptosis-Inducing Effect of Chemotherapeutic Agents Is Potentiated by Soy Isoflavone Genistein, a Natural Inhibitor of NF- κ B in BxPC-3 Pancreatic Cancer Cell Line. Pancreas, 2004, 28, e90-e95.	0.5	111
365	Unusual case of antiphospholipid antibody syndrome presenting with extensive cutaneous infarcts in a patient on long-term procainamide therapy. American Journal of Hematology, 2003, 72, 154-154.	2.0	6
366	Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. Urology, 2003, 61, 774-780.	0.5	106
367	Comparison of DNA Content Parameters in Paired, Fresh Tissue Pretreatment Biopsies and Surgical Resections from Squamous Cell Carcinoma of the Head and Neck. Otolaryngology - Head and Neck Surgery, 2003, 128, 169-177.	1.1	3
368	Developments in the Systemic Therapy of Pancreatic Cancer. Cancer Investigation, 2003, 21, 73-86.	0.6	30
369	Phase II Study of Gemcitabine, Cisplatin, and Infusional Fluorouracil in Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2003, 21, 2920-2925.	0.8	49
370	Breast Cancer in Women with Human Immunodeficiency Virus Infection: Implications for Diagnosis and Therapy. Breast Cancer Research and Treatment, 2002, 76, 111-116.	1.1	26